America as we know it was built largely upon and because of our rail industry, and today it remains…
So-Called "Railway Safety Act" Constitutes a Political Handout to Big Labor That Does Nothing to Improve Safety At All
America as we know it was built largely upon and because of our rail industry, and today it remains a pillar of our economy.
Unfortunately, a destructive proposal before Congress misleadingly named the "Railway Safety Act" (RSA), part of broader surface transportation reauthorization, threatens great harm to our railroads.
Simply put, the bill has nothing to do with improving safety, but has a lot to do with advancing the political agenda of Big Labor. At a moment when inflation burdens American families and fragile supply chains remain vulnerable to disruption, the last thing our economy or rail sector need is another costly federal mandate imposed upon one of the nation’s most important transportation sectors.
As an initial matter, as noted by The Wall Street Journal, the…[more]
Phil Kerpen, President and Founder of American Commitment, discusses the recent drug-pricing deal negotiated by the Trump administration with the United Kingdom, the multiple benefits the agreement will have for Americans and drug innovation, why taxpayer subsidies to health insurers will not lower healthcare costs, and why price controls for credit card transactions are a bad idea.
Rowena Itchon, Chief Operating Officer at the Pacific Research Institute, discusses a series of short videos released by PRI to bring to life the unsung heroes who have contributed remarkably to American innovation and success over the last 250 years and who embodied the spirit and values that make this country truly exceptional: self-reliance, innovation and civic responsibility.
Ryan Young, Senior Economist and Trade Policy Expert at the Competitive Enterprise Institute, discusses last year’s regulatory highlights (and low points), the regulatory outlook for 2025, including the potential impact of DOGE on the volume of federal regulations, and President Biden’s baseless decision to block Nippon Steel’s purchase of U.S. Steel.
Sally Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, discusses President Trump’s recent executive order regarding drug pricing, how importing foreign drug price controls could curtail innovation and limit access to the newest drugs, and why the timing of such a policy is wrong amid the ongoing COVID-19 pandemic.
Timothy Lee, Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom, discusses President Trump's executive orders on drug pricing and the negative consequences of government price controls on innovation and to consumers.
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
Leighton Steward, Chairman of Plants Need CO2, discusses a report from a team of former NASA scientists that concludes there is no convincing physical evidence of catastrophic human-caused global warming and the American people's rejection of President Obama's Global Climate Deal.